Background. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are innovative drugs that effectively reduce glycemic levels and overweight in patients with type 2 diabetes mellitus (T2DM). However. the criteria for predicting the hypoglycemic effect of this group of drugs have not been practically defined. https://www.royaltyfurnitureandappliancers.shop/product-category/jewelry-armoires/